Literature DB >> 1588920

Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens.

T Shimada1, C H Yun, H Yamazaki, J C Gautier, P H Beaune, F P Guengerich.   

Abstract

Rat and human lung microsomal cytochrome P-450 (P-450) enzymes have been characterized with regard to their catalytic activities towards several xenobiotic chemicals, including procarcinogens, in different microsomal preparations. Rat lung microsomal P-450s were more active than the human P-450s in catalyzing most of the monooxygenation reactions. Human lung microsomal P-450 was solubilized and purified. Human lung microsomes contain approximately 10 pmol of P-450/mg of protein, on the basis of Fe2+.CO versus Fe2+ difference spectra of the eluates obtained from an octylamino-agarose column. The partially purified P-450 preparations from two human lung microsomal samples showed high activities for the conversion of both (+)- and (-)-isomers of 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene to genotoxic products. After DEAE-cellulose column chromatography, a partially purified P-450 fraction containing polypeptides of Mr 52,000 and 58,000 was obtained from the early fraction of the octylamino-agarose column eluate, and an electrophoretically homogeneous protein having a molecular weight of approximately 52,000 was recovered from a latter fraction. The amino-terminal amino acid sequences of the two peptides in the earlier fraction were determined; neither polypeptide appears to resemble any known P-450 protein. The protein from the latter octylamino-agarose fraction was immunoreactive with anti-rat P-450 1A2 and anti-human P-450 1A2 but not with antibodies raised against other P-450 enzymes or autoimmune antibodies that specifically recognize human P-450 1A2. A tryptic peptide was isolated from the preparation, and the amino acid sequence matched that of human P-450 1A1 perfectly (residues 31-48) but not that of human P-450 1A2. All of nine human lung microsomal samples examined contained proteins that were immunoreactive with rabbit anti-rat P-450 1A2 and catalyzed the activation of 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene. The activities could be inhibited by rabbit anti-rat P-450 1A2 and, to a lesser extent, by anti-rat P-450 1A1. The addition of 7,8-benzoflavone caused inhibition or stimulation, depending upon the particular human lung microsomal preparation. Thus, this work clearly shows that human lung microsomes contain at least two major P-450 enzymes; human P-450 1A1 is present in lungs and can actually catalyze the activation of environmental procarcinogens, including polycyclic aromatic hydrocarbons.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1588920

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  29 in total

1.  Interactions of chemical carcinogens and genetic variation in hepatocellular carcinoma.

Authors:  Yu-Jing Zhang
Journal:  World J Hepatol       Date:  2010-03-27

2.  Analysis of r-7,t-8,9,c-10-tetrahydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene in human urine: a biomarker for directly assessing carcinogenic polycyclic aromatic hydrocarbon exposure plus metabolic activation.

Authors:  Yan Zhong; Steven G Carmella; J Bradley Hochalter; Silvia Balbo; Stephen S Hecht
Journal:  Chem Res Toxicol       Date:  2010-11-04       Impact factor: 3.739

3.  Biotransformation of caffeine by cDNA-expressed human cytochromes P-450.

Authors:  H R Ha; J Chen; S Krahenbuhl; F Follath
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 4.  Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism.

Authors:  M Pirmohamed; S Madden; B K Park
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

5.  Relationship among metabolizing genes, smoking and alcohol used as modifier factors on prostate cancer risk: exploring some gene-gene and gene-environment interactions.

Authors:  Dante D Cáceres; Jeannette Iturrieta; Cristian Acevedo; Christian Huidobro; Nelson Varela; Luis Quiñones
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

6.  Metabolism of theophylline by cDNA-expressed human cytochromes P-450.

Authors:  H R Ha; J Chen; A U Freiburghaus; F Follath
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

7.  Genetic contribution of CYP1A1 variant on treatment outcome in epilepsy patients: a functional and interethnic perspective.

Authors:  P Talwar; N Kanojia; S Mahendru; R Baghel; S Grover; G Arora; G K Grewal; S Parween; A Srivastava; M Singh; S Vig; S Kushwaha; S Sharma; K Bala; S Kukreti; R Kukreti
Journal:  Pharmacogenomics J       Date:  2016-03-08       Impact factor: 3.550

8.  An association between BPDE-like DNA adduct levels and CYP1A1 and GSTM1 polymorphisma in pterygium.

Authors:  Jai-Nien Tung; Heng-Hsiung Wu; Chun-Chi Chiang; Yi-Yu Tsai; Ming-Chih Chou; Huei Lee; Ya-Wen Cheng
Journal:  Mol Vis       Date:  2010-04-08       Impact factor: 2.367

9.  CYP1A1 gene polymorphisms as a risk factor for pterygium.

Authors:  Chi-Hsien Young; Yu-Lun Lo; Yi-Yu Tsai; Tung-Sheng Shih; Huei Lee; Ya-Wen Cheng
Journal:  Mol Vis       Date:  2010-06-09       Impact factor: 2.367

10.  CYP1A1 gene polymorphisms increase lung cancer risk in a high-incidence region of Spain: a case control study.

Authors:  Carmen San Jose; Agustin Cabanillas; Julio Benitez; Juan Antonio Carrillo; Mercedes Jimenez; Guillermo Gervasini
Journal:  BMC Cancer       Date:  2010-08-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.